In the advanced NSCLC patients, the interim results of NCT03732274 showed that galunisertib (TGFβRI kinase inhibitor) combined with durvalumab (anti-PD-L1) had potent antitumor activity with a manageable safety profile (response rate: 30.8% for PD-L1≥1% tumors; response rate: 40.0% for PDL1≥25%) (141). The gene discussed is CD274; the disease is non-small cell lung carcinoma.